The migraine prophylaxis market is poised for disruption as four anti-CGRP monoclonal antibodies (MAbs) race to market. Amgen/Novartis’s Aimovig (erenumab) is in the pole position, and has become the first migraine-specific preventative therapy, the first major new entrant, and the first biologic to enter this market since the approval of Allergan’s Botox in 2010. With three additional anti-CGRP MAbs (e.g., Teva’s fremanezumab, Eli Lilly’s galcanezumab, and Alder’s eptinezumab) expected to launch for the treatment of migraine prevention by 2020.
The infographic below gathers together DRG epidemiology, primary market research, and U.S. claims data to explore the opportunity that awaits these innovative therapies in the highly underserved but heavily generic migraine prophylaxis market.
For more information on the migraine market, browse our recent reports here.